10 drug companies that normally compete against each other, including giants Sanofi and Pfizer, will now cooperate not just with government researchers and non-profits, but with each other as part of a five-year, $230 million partnership to speed up the pace of new drug development in several key conditions Alzheimer's disease, type 2 diabetes, rheumatoid arthritis and lupus according to an announcement from the National Institutes of Health.
10 drug companies that normally compete against each other, including giants Sanofi and Pfizer, will now cooperate not just with government researchers and non-profits, but with each other as part of a five-year, $230 million partnership to speed up the pace of new drug development in several key conditions Alzheimer's disease, type 2 diabetes, rheumatoid arthritis and lupus according to an announcement from the National Institutes of Health.
In the article, our director of chemical and pharmaceutical sciences, Dr. Josh Bloom, noted that though $230 million is "one-tenth the amount it takes to discover and develop a single drug," the early phases of drug research tend to be the least expensive, so this is a good start.
